← 返回

首届神经介入外科学会神经介入肿瘤学峰会报告

英文原题:A Report from the Inaugural Society of NeuroInterventional Surgery Neurointerventional Oncology Summit.

查看英文原题

A Report from the Inaugural Society of NeuroInterventional Surgery Neurointerventional Oncology Summit.

PubMed 2026/01/05(内容时间) AJNR Am J Neuroradiol Q2 · IF 3.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过去25年来,CNS肿瘤的治疗进展有限,胶质母细胞瘤和弥漫性内生性桥脑胶质瘤等恶性肿瘤的结局仍然不佳。利用血管内神经介入技术,将脑血管系统作为神经肿瘤学治疗递送途径,引起了极大的兴趣。目前有几项选择性动脉内临床试验正在进行中,针对一系列CNS肿瘤使用不同的治疗药物。神经介入外科学会(SNIS)召开了首届神经介入肿瘤学峰会,于2024年4月26-27日在德克萨斯州休斯顿的德克萨斯大学MD Anderson癌症中心举行。该小组由神经介入医师、神经外科医师、神经肿瘤学家、神经放射学家、基础科学家和行业代表组成,他们都是这一新兴领域的当前从业者。

我们报告当前的实践现状,以及我们为治疗CNS癌症患者和推动这一新兴领域研究而开发组织平台的努力。血管内外科神经肿瘤学是一项新兴的临床事业,旨在为CNS癌症提供新的治疗选择。新型治疗药物,包括钇-90、溶瘤病毒和细胞免疫治疗,正在作为动脉内治疗进行测试。影像模态的技术进步、选择性BBB开放方法以及装置和导管将有助于推动该领域的发展。多学科合作与协作将是这一事业成功的关键。

展开英文摘要原文

Over the past 25 years, progress in the treatment of CNS tumors has been limited, and outcomes for malignancies, such as glioblastoma and diffuse intrinsic pontine glioma, remain dismal. There has been great interest in harnessing endovascular neurointerventional techniques and using the cerebral vasculature as a route for therapeutic delivery in neuro-oncology. Several selective intra-arterial clinical trials are currently underway targeting a range of CNS tumors with different therapeutic agents.

The Society of NeuroInterventional Surgery (SNIS) convened the inaugural Neurointerventional Oncology Summit, which was held on April 26-27, 2024, at the University of Texas MD Anderson Cancer Center in Houston, Texas. The group consisted of neurointerventionists, neurosurgeons, neuro-oncologists, neuroradiologists, basic scientists, and industry representatives who are current practitioners in this emerging space.

We report the current state of practice and our efforts to develop an organizational platform to treat patients with CNS cancers and to advance research in this emerging field. Endovascular surgical neuro-oncology is an emerging clinical endeavor that aims to provide novel therapeutic options for CNS cancers.

Novel therapeutic agents, including yttrium-90, oncolytic viruses, and cellular immunotherapy, are being tested as intra-arterial therapy. Technological advances in imaging modalities, selective methods of BBB opening, and devices and catheters will aid the advancement of the field. Multidisciplinary cooperation and collaboration will be integral to the success of this endeavor.

论文信息

作者
Young CC、Narsinh KH、Chen SR、Ansari SA、Hetts SW、Lang FF、Wintermark M、Kan PT
单位
From the Department of Neurosurgery (C.C.Y., S.R.C., F.F.L.), University of Texas MD Anderson Cancer Center, Houston, Texas ccyoung1@mdanderson.org.United States
文献类型
会议论文集 · 非美国政府资助研究 · 美国 NIH 资助研究
期刊
AJNR. American journal of neuroradiology2026 Jan 5
原文标识
PubMed 40592540 · DOI 10.3174/ajnr.A8902